drugset / Trial / NCT02169713

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects

NCT02169713

Phase 1 Completed 20 enrolled Astellas Pharma Europe B.V.
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to evaluate the effect of solifenacin and mirabegron on the concentrations of tamsulosin HCl after combined dosing. This study will also evaluate the safety and tolerability of the combined administration of solifenacin, mirabegron and tamsulosin HCl.

Timeline

Start
2014-05
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified Oral
Subject Solifenacin Small molecule Oral
Subject Tamsulosin Other / unclassified Oral

Indications

No indication recorded.